HaemaLogiX executive director and chief scientific officer Dr Rosanne Dunn talked with Proactive about the TGA approval for a Phase 1 clinical trial of the company’s novel KMCAR™ T-cell immunotherapy for multiple myeloma.
Dunn explained that this milestone marks the first clinical trial using HaemaLogiX’s CAR-T cell platform, which modifies a patient’s own T cells to directly recognise and kill myeloma cells. She highlighted the therapy’s specificity, noting that it targets a unique marker found only on myeloma cells, which may support a stronger safety profile compared to existing treatments.
Dunn noted that while CAR-T therapies are highly promising, HaemaLogiX’s broader pipeline aims to improve both survival and quality of life for patients with multiple myeloma, a disease still considered incurable.
For more updates on emerging biotech breakthroughs, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications so you never miss future content.
#HaemaLogiX #CAR_T #MultipleMyeloma #BiotechNews #ClinicalTrials #Immunotherapy #CancerResearch #TGAApproval #HealthcareInnovation #KMCAR #BiotechInvesting #Oncology #MedicalBreakthrough #LifeSciences #DrugDevelopment